Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivarmacitinib - Arcutis Biotherapeutics/Jiangsu HengRui Medicine

Next Previous
Drug Profile

Ivarmacitinib - Arcutis Biotherapeutics/Jiangsu HengRui Medicine

Alternative Names: ARQ-252; ARQ-255; Ivarmacitinib sulfate; SHR-0302

Latest Information Update: 28 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Arcutis Biotherapeutics; Jiangsu Hengrui Medicine Co.; Reistone Biopharma
  • Class 2 ring heterocyclic compounds; Amides; Amines; Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Cyclopentanes; Heterocyclic bicyclo compounds; Methyl ethers; Pyrimidines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules; Sulfates; Thiadiazoles
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alopecia areata; Ankylosing spondylitis; Atopic dermatitis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Vitiligo
  • Phase II Crohn's disease; Peripheral T-cell lymphoma
  • Preclinical Eczema
  • No development reported Graft-versus-host disease

Most Recent Events

  • 28 Jun 2026 No recent reports of development identified for phase-I development in Graft-versus-host-disease(In volunteers) in China (PO, Liquid)
  • 28 Jun 2026 No recent reports of development identified for phase-I development in Graft-versus-host-disease(In volunteers) in China (PO, Tablet)
  • 06 Jun 2026 Efficacy and adverse event data from a phase III trial in Axial spondyloarthritis presented at the at 27th Annual Congress of the European League Against Rheumatism (EULAR-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top